Transcriptome analysis of K-877 (A novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 8, 2015, Pages 754-772

  Raza Iqbal, Sana ^a   Tanaka, Toshiya ^a,b   Anai, Motonobu ^a   Inagaki, Takeshi ^a,b   Matsumura, Yoshihiro ^a   Ikeda, Kaori ^b   Taguchi, Akashi ^a   Gonzalez, Frank J ^c   Sakai, Juro ^a,b   Kodama, Tatsuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Species difference; SPPARM ; Transcriptome

Indexed keywords

ABC TRANSPORTER A1; MANNOSE BINDING LECTIN 2; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTOME; ANTILIPEMIC AGENT; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; FENOFIBRATE; FENOFIBRIC ACID; K-877 COMPOUND;

ADULT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DYSLIPIDEMIA; ENPEP GENE; FATTY ACID METABOLISM; FEMALE; FGF21 GENE; GENE; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; LIVER; LIVER CELL; LIVER TOXICITY; LUCIFERASE ASSAY; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEROXISOME; VLDLR GENE; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE TECHNIQUE; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; PATHOLOGY; TISSUE CULTURE TECHNIQUE;

ANIMALS; BENZOXAZOLES; BUTYRATES; CELL CULTURE TECHNIQUES; CLUSTER ANALYSIS; FENOFIBRATE; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER; MICE; TISSUE CULTURE TECHNIQUES; TRANSCRIPTOME;

EID: 84940377283     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.28720     Document Type: Article

References (60)

1. Hotamisligil GS: Inflammation and metabolic disorders. Nature, 2006; 444: 860-867
2. Wierzbicki AS: Fibrates after the FIELD study: Some answers, more questions. Diab Vasc Dis Res, 2006; 3: 166-171
3. Fruchart JC: Peroxisome proliferator-activated receptor-α (PPARα): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis, 2009; 205: 1-8
4. Fruchart JC: Selective peroxisome proliferator-activated proreceptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol, 2013; 12: 82
5. Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC: Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorg Med Chem Lett, 2007; 17: 4689-4693
6. Ishibashi S, Ymashita S, Arai H, Araki E, Yokote K, Kodama T: Efficacy and safety of K-877, a potent and selective PPAR-α agonist, in Japanese patients with dyslipidemia. American Heart Association, Scientific sessions 2013, 2013; poster 2002
7. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA, 2001; 98: 5306-5311
8. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J: Activation of peroxisome proliferator-activated receptor δ induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA, 2003; 100: 15924-15929
9. Akita N, Tsujita M, Yokota T, Gonzalez FJ, Ohte N, Kimura G, Yokoyama S: High density lipoprotein turnover is dependent on peroxisome proliferator-activated receptor α in mice. J Atheroscler Thromb, 2010; 17: 1149-1159
10. Tanaka T, Tahara-Hanaoka S, Nabekura T, Ikeda K, Jiang S, Tsutsumi S, Inagaki T, Magoori K, Higurashi T, Takahashi H, Tachibana K, Tsurutani Y, Raza S, Anai M, Minami T, Wada Y, Yokote K, Doi T, Hamakubo T, Auwerx J, Gonzalez FJ, Nakajima A, Aburatani H, Naito M, Shibuya A, Kodama T, Sakai J: PPARβ/δ activation of CD300a controls intestinal immunity. Sci Rep, 2014; 4: 5412
11. Rodríguez JC, Gil-Gómez G, Hegardt FG, Haro D: Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J Biol Chem, 1994; 269: 18767-18772
12. Wu P, Peters JM, Harris RA: Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor α. Biochem Biophys Res Commun, 2001; 287: 391-396
13. Martin G, Poirier H, Hennuyer N, Crombie D, Fruchart JC, Heyman RA, Besnard P, Auwerx J: Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. J Biol Chem, 2000; 275: 12612-12618
14. Huang B, Wu P, Bowker-Kinley MM, Harris RA: Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-α ligands, glucocorticoids, and insulin. Diabetes, 2002; 51: 276-283
15. Kersten S: Integrated physiology and systems biology of PPARα. Mol Metab, 2014; 3: 354-371
16. Dalen KT, Ulven SM, Arntsen BM, Solaas K, Nebb HI: PPARα activators and fasting induce the expression of adipose differentiation-related protein in liver. J Lipid Res, 2006; 47: 931-943
17. Nourbakhsh M, Douglas DN, Pu CH, Lewis JT, Kawahara T, Lisboa LF, Wei E, Asthana S, Quiroga AD, Law LM, Chen C, Addison WR, Nelson R, Houghton M, Lehner R, Kneteman NM: Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. J Hepatol, 2013; 59: 336-343
18. Fiermonte G, Paradies E, Todisco S, Marobbio CM, Palmieri F: A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3’,5’-diphosphate in human mitochondria. J Biol Chem, 2009; 284: 18152-18159
19. Bumpus NN, Johnson EF: 5-Aminoimidazole-4-carboxyamide- ribonucleoside (AICAR)-stimulated hepatic expression of Cyp4a10, Cyp4a14, Cyp4a31, and other peroxisome proliferator-activated receptor α-responsive mouse genes is AICAR 5’-monophosphate-dependent and AMPactivated protein kinase-independent. J Pharmacol Exp Ther, 2011; 339: 886-895
20. Kim YJ, Cho SY, Yun CH, Moon YS, Lee TR, Kim SH: Transcriptional activation of Cidec by PPARγ2 in adipocyte. Biochem Biophys Res Commun, 2008; 377: 297-302
21. Dongol B, Shah Y, Kim I, Gonzalez FJ, Hunt MC: The acyl-CoA thioesterase I is regulated by PPARα and HNF4α via a distal response element in the promoter. J Lipid Res, 2007; 48: 1781-1791
22. Hunt MC, Lindquist PJ, Nousiainen S, Huttunen M, Orii K, Svensson TL, Aoyama T, Hashimoto T, Diczfalusy U, Alexson SE: Acyl-CoA thioesterases belong to a novel gene family of peroxisome proliferator-regulated enzymes involved in lipid metabolism. Cell Biochem Biophys, 2000; 32: 317-324
23. Hunt MC, Nousiainen SE, Huttunen MK, Orii KE, Svensson LT, Alexson SE: Peroxisome proliferator-induced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism. J Biol Chem, 1999; 274: 34317-34326
24. Rommelaere S, Millet V, Gensollen T, Bourges C, Eeckhoute J, Hennuyer N, Baugé E, Chasson L, Cacciatore I, Staels B, Pitari G, Galland F, Naquet P: PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett, 2013; 587: 3742-3748
25. van Diepen JA, Jansen PA, Ballak DB, Hijmans A, Hooiveld GJ, Rommelaere S, Galland F, Naquet P, Rutjes FP, Mensink RP, Schrauwen P, Tack CJ, Netea MG, Kersten S, Schalkwijk J, Stienstra R: PPAR-alpha dependent regulation of vanin-1 mediates hepatic lipid metabolism. J Hepatol, 2014; 61: 366-372
26. Jiang YJ, Kim P, Lu YF, Feingold KR: PPARgamma activators stimulate aquaporin 3 expression in keratinocytes/ epidermis. Exp Dermatol. 2011; 20: 595-599
27. Jancova P, Anzenbacher P, Anzenbacherova E: Phase Ⅱ drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010; 154: 103-116
28. Gonzalez FJ, Shah YM: PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proreceptor speliferators. Toxicology, 2008; 246: 2-8
29. Hunt MC, Tillander V, Alexson SE: Regulation of peroxisomal lipid metabolism: the role of acyl-CoA and coenzyme A metabolizing enzymes. Biochimie, 2014; 98: 45-55
30. Steinberg SJ, Dodt G, Raymond GV, Braverman NE, Moser AB, Moser HW: Peroxisome biogenesis disorders. Biochim Biophys Acta, 2006; 1763: 1733-1748
31. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res, 1996; 37: 907-925
32. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O’Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev, 2006; 58: 726-741
33. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest, 2006; 116: 571-580
34. Miyazaki M, Nakagawa I, Koga S, Kasahara Y, Patricelli MP: Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor α (PPARα) stimulation. J Toxicol Sci, 2010; 35: 131-135
35. Vilà-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF: Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem, 2011; 286: 20423-20430
36. Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK: Characterization and tissue-specific expression of the human ‘very low density lipoprotein (VLDL) receptor’ mRNA. Hum Mol Genet, 1994; 3: 531-537
37. Gao Y, Shen W, Zhang Q, Hu Y, Chen Y: Up-regulation of Hepatic VLDLR via PPARα Is Required for the Triglyceride- Lowering Effect of Fenofibrate. J Lipid Res, 2014; 55: 1622-1633
38. Li H, Zhang J, Jia W: Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. Front Med, 2013; 7: 25
39. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB: FGF-21 as a novel metabolic regulator. J Clin Invest, 2005; 115: 1627-1635
40. Véniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, Zhou L, Wada R, Hecht R, Xu J: Longacting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology, 2012; 153: 4192-4203
41. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA: Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab, 2007; 5: 415-425
42. Lundåsen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M: PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun, 2007; 360: 437-440
43. Kim H, Mendez R, Zheng Z, Chang L, Cai J, Zhang R, Zhang K: Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. Endocrinology, 2014; 155: 769-782
44. Yokote K, Ishibashi S, Yamashita S, Arai H, Araki E, Kodama T: Marked Increase of Plasma Fibroblast Growth Factor 21 in Dyslipidemic Patients Treated With K-877, a Novel Highly Potent and Specific Peroxisome Proliferator- Activated Receptor Alpha Agonist. American Heart Association Scientific Sessions 2013, 2013; Abstract 17336
45. Van Eck M: ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level. Curr Opin Lipidol, 2014; 25: 297-303
46. Yin K, Liao DF, Tang CK: ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol Med, 2010; 16: 438-449
47. Ammerschlaeger M, Beigel J, Klein KU, Mueller SO: Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci, 2004; 78: 229-240
48. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF: Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol, 1998; 53: 14-22
49. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM: Mannose- binding lectin and innate immunity. Immunol Rev, 2009; 230: 9-21
50. Megia A, Gallart L, Fernández-Real JM, Vendrell J, Simón I, Gutierrez C, Richart C: Mannose-binding lectin gene polymorphisms are associated with gestational diabetes mellitus. J Clin Endocrinol Metab, 2004; 89: 5081-5087
51. Mizutani S, Ishii M, Hattori A, Nomura S, Numaguchi Y, Tsujimoto M, Kobayshi H, Murohara T, Wright JW: New insights into the importance of aminopeptidase A in hypertension. Heart Fail Rev, 2008; 13: 273-284
52. Mitsui T, Nomura S, Okada M, Ohno Y, Kobayashi H, Nakashima Y, Murata Y, Takeuchi M, Kuno N, Nagasaka T, O-Wang J, Cooper MD, Mizutani S: Hypertension and angiotensin Ⅱ hypersensitivity in aminopeptidase A-deficient mice. Mol Med, 2003; 9: 57-62
53. Omori Y, Imai J, Watanabe M, Komatsu T, Suzuki Y, Kataoka K, Watanabe S, Tanigami A, Sugano S: CREBH: a novel mammalian transcription factor belonging to the CREB/ATF family and functioning via the box-B element with a liver-specific expression. Nucleic Acids Res, 2001; 29: 2154-2162
54. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ: Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell, 2006; 124: 587-599
55. Lee MW, Chanda D, Yang J, Oh H, Kim SS, Yoon YS, Hong S, Park KG, Lee IK, Choi CS, Hanson RW, Choi HS, Koo SH: Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab, 2010; 11: 331-339
56. Zhang C, Wang G, Zheng Z, Maddipati KR, Zhang X, Dyson G, Williams P, Duncan SA, Kaufman RJ, Zhang K: Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte speliferators. cific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. Hepatology, 2012; 55: 1070-1082
57. Danno H, Ishii KA, Nakagawa Y, Mikami M, Yamamoto T, Yabe S, Furusawa M, Kumadaki S, Watanabe K, Shimizu H, Matsuzaka T, Kobayashi K, Takahashi A, Yatoh S, Suzuki H, Yamada N, Shimano H: The liver-enriched transcription factor CREBH is nutritionally regulated and activated by fatty acids and PPARα. Biochem Biophys Res Commun, 2010; 391: 1222-1227
58. Nishimura J, Dewa Y, Okamura T, Muguruma M, Jin M, Saegusa Y, Umemura T, Mitsumori K: Possible involve ment of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats. Arch Toxicol, 2008; 82: 641-654
59. Park EY, Cho IJ, Kim SG: Transactivation of the PPARresponsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferatoractivated receptor-γ and retinoid X receptor heterodimer. Cancer Res, 2004; 64: 3701-3713
60. Kim H, Mendez R, Zheng Z, Chang L, Cai J, Zhang R, Zhang K: Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. Endocrinology, 2014; 155: 769-782